Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Given Consensus Recommendation of “Strong Sell” by Brokerages

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has earned a consensus rating of “Strong Sell” from the nine research firms that are presently covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a sell rating and four have given a hold rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $28.00.

Several analysts have issued reports on FMS shares. Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, May 6th. Zacks Research lowered Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 27th. Citigroup reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday, April 24th. Wall Street Zen lowered Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings lowered Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

Several large investors have recently modified their holdings of FMS. CIBC Private Wealth Group LLC lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 398.2% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock valued at $36,000 after purchasing an additional 1,103 shares during the last quarter. Arax Advisory Partners lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 121.6% in the 4th quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock valued at $38,000 after purchasing an additional 885 shares during the last quarter. Kestra Advisory Services LLC acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA in the 4th quarter valued at $48,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA in the 4th quarter valued at $58,000. Finally, Group One Trading LLC acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA in the 3rd quarter valued at $74,000. Institutional investors and hedge funds own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Stock Up 0.0%

Shares of FMS opened at $23.59 on Tuesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.86 and a current ratio of 1.20. Fresenius Medical Care AG & Co. KGaA has a one year low of $20.02 and a one year high of $28.86. The stock has a market capitalization of $12.74 billion, a price-to-earnings ratio of 12.42, a PEG ratio of 4.26 and a beta of 0.80. The stock has a 50 day moving average price of $22.32 and a 200 day moving average price of $22.84.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its earnings results on Tuesday, March 31st. The company reported $1.05 earnings per share (EPS) for the quarter. The company had revenue of $5.34 billion during the quarter. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.90% and a net margin of 4.88%. Equities research analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 2.24 earnings per share for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Increases Dividend

The firm also recently declared an annual dividend, which was paid on Monday, June 8th. Stockholders of record on Friday, May 22nd were paid a $0.8716 dividend. This is a boost from Fresenius Medical Care AG & Co. KGaA’s previous annual dividend of $0.79. The ex-dividend date of this dividend was Friday, May 22nd. This represents a dividend yield of 402.0%. Fresenius Medical Care AG & Co. KGaA’s dividend payout ratio is currently 32.11%.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.